Skip to Main Content

2,334

Views

1

CrossRef citations to date

0

Altmetric

Original Articles

Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML

Ellen K. Ritchiea Department of Medicine, Weill Cornell Medicine, New York City, NY, USACorrespondence[email protected]
View further author information

,

David Cellab Department of Medical Social Sciences, Northwestern University, Feinberg School of Medicine, Chicago, IL, USAView further author information

,

Francesco Fabbianoc Department of Hematology, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, ItalyView further author information

,

Arnaud Pigneuxd Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, FranceView further author information

,

Yoshinobu Kandae Division of Hematology, Jichi Medical University, Tochigi, JapanView further author information

,

Cristina Ivanescuf Patient Centered Solutions, IQVIA, Amsterdam, NetherlandsView further author information

,

Bhavik J. Pandyag Medical Affairs, Astellas Pharma, Inc., Northbrook, IL, USAView further author information

&

Manasee V. Shahg Medical Affairs, Astellas Pharma, Inc., Northbrook, IL, USAView further author information